# A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Study · id `cardio:ct-nct05769608` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05769608](<https://clinicaltrials.gov/study/NCT05769608>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05769608

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 285 participants.

## Technical summary

Registry record NCT05769608. Randomized; double masking; primary purpose treatment. Start 2023-03-13 (actual); primary completion 2025-01-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 285 participants (enrolled count; ClinicalTrials.gov record NCT05769608, source copy `cardio:ctgov-nct05769608-2026-01-20`, retrieved 2026-10-26)
- Started: 2023-03-13 (actual) (ClinicalTrials.gov record NCT05769608, source copy `cardio:ctgov-nct05769608-2026-01-20`, retrieved 2026-10-26)
- Primary completion: 2025-01-15 (actual) (ClinicalTrials.gov record NCT05769608, source copy `cardio:ctgov-nct05769608-2026-01-20`, retrieved 2026-10-26)
- Completion: 2025-01-15 (actual) (ClinicalTrials.gov record NCT05769608, source copy `cardio:ctgov-nct05769608-2026-01-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05769608, source copy `cardio:ctgov-nct05769608-2026-01-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05769608-2026-01-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
- Condition: Hypertension
- Intervention (Drug): Placebo
- Intervention (Drug): lorundrostat Dose 1
- Intervention (Drug): lorundrostat Dose 2
- Lead sponsor: Mineralys Therapeutics Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Mineralys Therapeutics Inc. (`cardio:org-mineralys-therapeutics-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension (`cardio:pubmed-40267417`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d2436d84e68d4e39b6419274327e5a318219f8069393569df3447ed4e927bcc2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
